Search
Killer antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Read morePress Release: News on Red Cells and Iron presented at the 18th Congress of the European Hematology Asscociation in Stockholm June 13-16, 2013
Recent evidence suggests that these congenital anaemias are caused by molecular abnormalities in the transport of iron and other molecules and a deeper understanding of these mechanisms may lead to a better knowledge of the normal development of the red…
Read moreCurriculum-Exam Committee
Current committee members
Jose Tomás Navarro Ferrando, Spain (Chair)
Marielle Wondergem, The Netherlands (Vice-Chair and Progress test lead)
Alicia Rovó, Switzerland (Representative, Swiss Society)
Regular members
Gunnar Birgegård, Sweden
Roza Chaireti, Sweden
Carlos Fernández de Larrea, Spain
Mahesh Prahladan, United Kingdom
Ulla Wartiovaara-Kautto, Finland
AimTo promote harmonization in hematology training…
More than science: the European Affairs program at EHA2023
To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.
Read moreRegistration & accommodation
Registration is closed
Individual RegistrationRegistration fee includes:
Access to the scientific and educational sessions of the meeting
Digital meeting materials including the program and abstract book
Networking opportunities during breaks, receptions and dinners
Catering during meeting hours incl.
Renew your membership
If you want to keep enjoying the benefits of EHA membership— from around-the-clock access to EHA Campus to discounts on EHA Congress registration—you'll need to renew your membership.
Read moreWhat to expect
FacultyThe faculty is made up of international leaders in clinical hematology research, statisticians, experts in regulatory and ethical aspects of clinical research and more.
Read moreImproved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »